Evidence
SomaBiome is grounded in peer-reviewed microbiome research across fibromyalgia and chronic pain conditions.
Selected Publications
Fibromyalgia
PAIN, 2019
Altered microbiome composition in individuals with fibromyalgia
Identified species-level microbiome alterations associated with symptom severity and metabolomic shifts in a case-control cohort.
Fibromyalgia & Bile Acids
PAIN, 2022
Altered serum bile-acid profile in fibromyalgia is associated with specific gut microbiome changes and symptom severity
Identified associations between serum bile acid profiles, specific gut microbiome alterations, and symptom severity in a retrospective fibromyalgia cohort.
Fibromyalgia & Diet
IJERPH, 2022
Dietary Intake Is Unlikely to Explain Symptom Severity and Syndrome-Specific Microbiome Alterations in a Cohort of Women with Fibromyalgia
Demonstrated that dietary intake does not account for observed microbiome alterations, strengthening the interpretation of a disease-specific biological signal.
External Mechanistic Evidence
Neuron, 2025
Peer-reviewed research supporting microbiome–pain biology
External evidence providing mechanistic insights into the gut-brain axis and its relevance to chronic pain signaling and sensory processing.
We include select non-fibromyalgia publications that demonstrate cross-cohort reproducibility in chronic pain and causal microbiome-to-host mechanisms that inform our analytical approach.
Chronic Pain Generalization
Anesthesiology, 2025
Gut microbiome signatures in Complex Regional Pain Syndrome (CRPS)
Demonstrated reproducible microbiome signatures across independent cohorts and geographies, suggesting a generalized signal for chronic pain.
Mechanistic Validation
Gut, 2023
Gut microbiota influence anastomotic healing in colorectal cancer surgery through modulation of mucosal proinflammatory cytokines
Demonstrated causal links between gut microbiome composition and anastomotic healing. Identified Alistipes onderdonkii as a driver of leak risk and Parabacteroides goldsteinii as a protective factor modulating mucosal proinflammatory cytokines.
Selected coverage
- Nature News — "Baffling chronic pain eases after doses of gut microbes" (Apr 24, 2025) — https://doi.org/10.1038/d41586-025-01290-x
- Nature Outlook: Pain — "The gut microbiome and chronic pain" (Sep 25, 2024) — https://doi.org/10.1038/d41586-024-03006-z
Media coverage discusses peer-reviewed research and does not constitute endorsement or clinical validation of any product.
Performance & Translation
Across published research cohorts, microbiome-based classifiers show ~90% case–control performance in retrospective research settings. SomaBiome is translating these findings into clinical decision support under development, designed for integration into routine clinic workflows.
Disclaimer: Performance metrics refer to retrospective analysis in research cohorts. Clinical validation in prospective real-world settings is ongoing. Not for consumer use.